# Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

> **NCT05895877** · PHASE3 · UNKNOWN · sponsor: **Synmosa Biopharma Corp.** · enrollment: 351 (estimated)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** Goofice®
- **DRUG:** Goofice® Placebo

## Key facts

- **NCT ID:** NCT05895877
- **Lead sponsor:** Synmosa Biopharma Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-21
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 351 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895877, "Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05895877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*